Background Cancer immunotherapy shows unique efficacy kinetics that differs from
conventional treatment. These characteristics may lead to the prolongation of trial duration …

Immune checkpoint inhibitors (ICIs) are a group of drugs designed to improve the
therapeutic effects on various types of malignant tumors. Irrespective of monotherapy or …

Background A total of 11 treatment sequences for advanced wild-type squamous non-small
cell lung cancer are recommended by Chinese Society of Clinical Oncology Guidelines …

Programmed cell death ligand 1 (PD-L1) expression remains the most widely used
biomarker for predicting response to immune checkpoint inhibitors (ICI), but its …

Abstract Aims As PD-L1 expression has been proposed as one of the cancer biomarkers for
non-small cell lung cancer (NSCLC), the predictive value of tumour proportional score (TPS) …

Increasing evidences have demonstrated the ferroptosis-related lncRNAs are key regulators
of non-small cell lung cancer (NSCLC) progression and new targets for NSCLC therapy …

Purpose Drug resistance inevitably occurs despite the encouraging results of
immunotherapy. This study attempted to investigate immunotherapy rechallenge treatment …

Objectives Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-
small cell lung cancer (NSCLC). However, the application of ICIs can also cause treatment …

Immune escape mechanisms in non-small cell lung cancer (NSCLC) can disrupt every step
of the anti-cancer immune response. In recent years, an increased understanding of the …

Immune checkpoint inhibitors (ICIs), such as programmed death-1 (PD-1), programmed
death-ligand 1 (PD-L1), cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies, etc, have …